GlobeNewswire by notified

Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – March 31, 2022


Message from the CEO

IBT's vision is to become an internationally leading company in the development of pharmaceuticals in the areas of premature infants, gastrointestinal diseases and probiotics.

We have now successfully driven the development of IBP-9414, the world's first phase III pharmaceutical grade probiotic for children, for almost a decade. The key milestone initiating the development of pharmaceutical grade probiotics occurred when IBT became the first company in the world in 2014 to receive Orphan Drug Designation in the US, where others had previously tried but failed. IBT subsequently became the first to be authorized by the FDA to administer live bacteria to children in a clinical trial in the US. The fact that we have also received permission to carry out pediatric studies in another 10 countries (9 EU + Israel) is further validation of IBT's unique ability to develop pharmaceutical grade probiotics.

Our work is attracting more and more attention. For example, The American Association of Pediatrics recently published that premature infants need pharmaceutically developed probiotics, mentioning our Phase III study in particular. The reason why IBT's work is specifically noticed is that probiotics should be of the highest safety, efficacy, and manufacturing standards when administered to premature babies. Today we know that premature babies can suffer injury and even death from the contaminants that can accompany a product that is not manufactured to the highest drug standards. IBT's production is well scrutinized by the FDA and corresponding authorities across 10 other countries. We have made ongoing investments since 2014 to ensure that our production yields a probiotic product intended to become the first to be approved as a drug.

We maintained good recruitment momentum in our NEC study through the fall of 2021, while omicron affected recruitment during the winter. As of today, May 4th, 2022, we have recruited 915 patients. It is difficult to assess what future recruitment rates will look like, but our focus on our phase III study remains and we expect to be able to complete recruitment in 2023 with existing capital.

During the first quarter of 2022, we initiated preparations for our commercialization phase of IBP-9414, where we are identifying and securing the resources and networks required to be prepared from day one in terms of product, market and organization prior to our launch.

In parallel, we have taken the first steps towards expanding IBT's product portfolio, which is based on the unique knowhow created by IBT. During the first quarter of 2022, we signed an agreement with a leading American university regarding the development of a potential new drug, separate from IBP-9414, in the treatment of a disease that can also affect those born prematurely. We are also in discussions with another American university regarding the rights to yet another medically meaningful treatment. I can also mention that we started our own gastroschisis project (IBP-1016) with, including a key opinion leader meeting in April.

In conclusion, I would like to take this opportunity to thank all the staff and experts around the world who with great commitment help us get closer to our vision through the development of pharmaceutical grade probiotics, especially with IBP-9414 which may play a very significant role for premature babies.

Stockholm, May 4, 2022

Staffan Strömberg

Financial overview for the period

First quarter (Jan-Mar) 2022

  • Net sales KSEK 0 (0)                                       
  • Operating income KSEK -19 063* (452)
  • Earnings per share before and after dilution SEK -1.71 (0.04)        

* Operational income includes exchange rate effects on foreign currency deposits for the purpose of securing future outflows during the first quarter amounting to KSEK 6,252 (12,114).

Significant events during the first quarter (Jan-Mar) 2022

  • On January 10, IBT announced that the Australian Patent Office has granted a patent entitled: “A method of activating lactic acid bacteria”.
  • On January 19, IBT announced that The Connection Study continues after the Data Monitoring Committee (DMC) had completed its pre-scheduled safety analysis without any concerns. At the same time a futility analysis was performed. Based on DMC recommendations and futility outcome, IBT is continuing the recruitment to the study as planned.

Significant events after the reporting period

  • The company's CFO, Michael Owens, has decided to retire during the year. A recruitment process has begun.
  • At the Annual General Meeting on May 4th 2022, Robert Molander resigned from the Board at his own request. At the same time, Robert is transferring to an operational role as Chief Commercial Officer within the management team for the company.

Selected financial data

Net sales---
Other income36494
Operating profit/loss-19 063452-44 578
Result after tax-19 201451-44 991
Total assets409 967451 138408 478
Cash flow for the period-10 825-9 794-55 532
Cash flow per share for the period (SEK)-0.96-0.87-4.95
Cash382 179425 758386 752
Earnings per share before and after dilution (SEK)-1.710.04-4.01
Equity per share (SEK) 33.5039.2635.21
Equity ratio (%)92%98%97%

About Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics AB (IBT) is a public company domiciled in Stockholm. The company’s Class B shares are listed on Nasdaq Stockholm, Small Cap (IBT B).

Infant Bacterial Therapeutics AB (publ) (IBT) is a pharmaceutical company with a product in clinical phase III with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants.

IBT is currently developing the drug candidate IBP-9414. The ambition for IBP-9414 is to become the world’s first approved probiotical drug with the goal to prevent life threatening diseases in premature infants including NEC and sepsis by promoting healthy stomach-and bowel development in premature infants. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. The product portfolio also includes another project, IBP-1016, for the treatment of gastroschisis, a severe and rare disease affecting infants. By developing these drugs, IBT has the potential to fulfill unmet needs for diseases where there are currently no prevention or treatment therapies available.

For additional information please contact

Staffan Strömberg, CEO
Infant Bacterial Therapeutics AB
Bryggargatan 10
111 21 Stockholm
Telephone: +46 76 219 37 38


The information was submitted for publication, through the agency of the contact persons set out above, at 18:00 CET on May 4, 2022.


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Nokia and Taiwan Mobile strengthen partnership with energy-efficient 5G coverage expansion deal26.5.2022 07:00:00 CEST | Press release

Press Release Nokia and Taiwan Mobile strengthen partnership with energy-efficient 5G coverage expansion deal New deal will see delivery of enhanced country-wide 5G coverage; Nokia’s energy-efficient AirScale portfolio will support TWM’s sustainability commitments Expansion of 5G Standalone Core includes slicing and low-latency edge cloud for enterprise, and Voice over New Radio (VoNR) 26 May 2022 Espoo, Finland – Nokia today announced that it has been selected by Taiwan Mobile (TWM) in an expansion deal to enhance the operator’s 5G coverage across the country. Under the deal, Nokia will provide its latest energy-efficient AirScale portfolio supporting TWM’s commitments to RE100 and reaching 100 percent renewable energy by 2040. It will also provide a smooth network evolution path following the completion of the proposed merger with Taiwan Star. Nokia will provide equipment from its AirScale portfolio, including base stations and massive MIMO antennas to boost network performance and c

Mandalay Resources Corporation Announces the Results of Its Annual General Meeting of Shareholders25.5.2022 23:32:49 CEST | Press release

TORONTO, May 25, 2022 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND, OTCQB: MNDJF) is pleased to announce the results of its Annual General Meeting of Shareholders (the “Meeting”) held today virtually. All the resolutions presented at the Meeting were approved by the shareholders, with the votes cast by proxy representing 67.63% of the total shares outstanding as of the record date. Election of Directors The number of directors was fixed at seven members and each of the seven nominees listed in the Company’s Management Information Circular dated April 14, 2022, were re-elected to the Company’s Board of Directors. Abraham Jonker remains the lead independent director and Bradford Mills continues as Chair. Results of the votes cast by proxy are set out below. ResolutionVotes Cast by Proxy For% ForVotes Cast by Proxy Withheld% WithheldBradford A. Mills61,552,12099.95329,1930.047Abraham Jonker61,551,31399.95130,0000.049Amy Freedman61,547,53899.94

Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European League Against Rheumatism congress25.5.2022 22:01:00 CEST | Press release

Celebrating EULAR’s 75thanniversary with focus on a new era of rheumatoid arthritis care Mechelen, Belgium;25 May 2022, 22.01CET;Galapagos NV (Euronext & Nasdaq: GLPG) will present 11 abstracts at the European League Against Rheumatism (EULAR) congress 2022, 01-04 June, taking place in Copenhagen, Denmark. The broad range of abstracts include trial data analyses supporting the efficacy and safety profile of filgotinib andreal-world clinical data around alignment of prescribing between physicians and rheumatoid arthritis (RA) patients. Galapagos is also hosting a hybrid symposium: “Evolving patient care in RA: Can JAK inhibitors meet patient and physician expectations for RA treatment?”, which will include a discussion focused on aligning physician and patient treatment goals, looking at what is meant by ‘comprehensive care’ and how to ensure that people living with RA are part of treatment and care goal setting. A meet-the-expert session, “Patient-centred care in RA: cutting through th

trivago N.V. Announces Annual General Meeting of Shareholders25.5.2022 21:39:06 CEST | Press release

trivago N.V. (NASDAQ: TRVG) announced today that its annual general meeting of shareholders will be held on June 30, 2022 at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands. The meeting will start at 3:00 p.m. CEST. The convening notice and explanatory notes for the general meeting are available free of charge in the Investor Relations section of trivago N.V.'s corporate website at About trivago N.V. trivago is a leading global hotel search platform focused on reshaping the way travelers search for and compare hotels and alternative accommodations. Incorporated in 2005 in Düsseldorf, Germany, the platform allows travelers to make informed decisions by personalizing their hotel search and providing them access to a deep supply of hotel information and prices. trivago enables its advertisers to grow their businesses by providing access to a broad audience of travelers via its websites and apps. As of March 31, 2022, trivago has est

Correction: Changes in Nokia Corporation's own shares25.5.2022 19:20:00 CEST | Press release

Nokia Corporation Stock Exchange Release 25 May 2022 at 20:20 EEST Correction: Changes in Nokia Corporation's own shares Espoo, Finland – This is a correction to "Changes in Nokia Corporation's own shares" stock exchange release that was published today at 19:30 EEST. A total of 183 965 Nokia shares (NOKIA) held by the company were today transferred without consideration to participants of Nokia's equity-based incentive plans in accordance with the rules of the plans. The transfer is based on the resolution of the Board of Directors to issue shares held by the company to settle its commitments to participants of the plans as announced on 3 February 2022. The number of own shares held by Nokia Corporation following the transfer is 61 262 561. This version is otherwise identical but now includes an updated total number of Nokia shares transferred (incorrect number was 188 636). About Nokia At Nokia, we create technology that helps the world act together. As a trusted partner for critical